Curasight news
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company.
With reference to the recently published positive results from the investigator-initiated phase
Curasight A/S (“Curasight” or the “Company”) has today signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.
Curasight has signed and completed an agreement to acquire all outstanding shares in TRT Innovations, which is a Danish early-stage R&D company focusing
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/35058319/).
Curasight A/S (“Curasight” or the “Company”) appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company.
<
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/).
The phase II study
The phase II
On Thursday, 7 October 2021, the exercise period for Curasight A/S (“Curasight” or “the Company”) warrants of series TO 1 (“TO 1”) ended. The warrant exercise has now been registered at Erhvervsstyrelsen. The total number of registered shares now amounts to 19,893,891 shares and the share capital amounts to DKK 994,694.55. The conversion from interim shares to ordinary shares will be made on Friday, 15 October 2021, and new shares are expected to be i
Curasight A/S (“Curasight” or “the Company”). In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons.
The Company’s managerial employees and their closely associated persons have given Curasight’s power of attorney on their behalf to publish tra
Curasight A/S (“Curasight” or the “Company”) has strengthened its institutional investor base as part of the company`s future strategy. Arbejdernes Landsbank has today acquired 200,000 warrants from the Swedish investment company Eastbridge, which is already a strategic investor in Curasight.
The transaction between Arbejdernes Landsbank and Eastbridge takes place as a so-called block trade, which means that the actual transfer of 200,0